Actively Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Led by Sanofi · Updated on 2026-04-08
208
Participants Needed
69
Research Sites
129 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 60 weeks for participants not transitioning into the long-term extension (LTE) study and will be up to approximately 52 weeks for participants transitioning into the LTE study. The randomized treatment duration will be up to approximately 48 weeks.
CONDITIONS
Official Title
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months before baseline
- HS lesions present in at least 2 different areas, with at least one area being Hurley Stage II or III
- Inadequate response, recurrence, intolerance, or contraindication to oral antibiotics for HS
- Biologic-naive or biologic-experienced participants
- Total abscess and inflammatory nodule count of 5 or more at baseline
- Draining tunnel count of 20 or fewer at baseline
You will not qualify if you...
- Presence of other active skin diseases or infections that interfere with HS assessment
- History of recurrent or recent serious infections
- Known significant immunosuppression
- History of solid organ or stem cell transplant
- History of splenectomy
- Moderate to severe congestive heart failure
- History of demyelinating disease or related neurological symptoms
- History of malignancy or lymphoproliferative disease except certain treated skin cancers
- Any condition that poses risk for participation per investigator's judgment
- Active suicidality or significant suicide risk
- Prior serious adverse events related to anti-TNF therapy contraindicating re-administration
- Sensitivity or allergy to study interventions or components
- History of significant prescription drug or substance abuse including alcohol within 2 years prior to baseline
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 69 locations
1
Northridge Clinical Trials - Northridge- Site Number : 8400005
Northridge, California, United States, 91325
Actively Recruiting
2
FXM Clinical Research - Miami- Site Number : 8400017
Miami, Florida, United States, 33175
Actively Recruiting
3
FXM Clinical Research Miramar, LLC - Site Number: 8400004
Miramar, Florida, United States, 33027
Actively Recruiting
4
Advanced Medical Research - Atlanta- Site Number : 8400011
Atlanta, Georgia, United States, 30342
Actively Recruiting
5
Georgia Skin & Cancer Clinic- Site Number : 8400009
Savannah, Georgia, United States, 31419
Actively Recruiting
6
The Iowa Clinic West Des Moines Campus- Site Number : 8400007
West Des Moines, Iowa, United States, 50266
Actively Recruiting
7
Louisiana Dermatology Associates- Site Number : 8400006
Baton Rouge, Louisiana, United States, 70809
Actively Recruiting
8
JDR Dermatology Research - Site number: 8400012
Las Vegas, Nevada, United States, 89145
Actively Recruiting
9
Clinical Partners- Site Number : 8400002
Johnston, Rhode Island, United States, 02919
Actively Recruiting
10
AMR Clinical South Strand, South Carolina- Site Number : 8400018
Myrtle Beach, South Carolina, United States, 29588
Actively Recruiting
11
Alpine Research Association- Site Number : 8400008
Layton, Utah, United States, 84041
Actively Recruiting
12
Investigational Site Number: 0360001
Liverpool, New South Wales, Australia, 2170
Actively Recruiting
13
Alfred Hospital - Site Number: 0360002
Melbourne, Victoria, Australia, 3004
Actively Recruiting
14
Interior Dermatology Centre - Site Number: 1240003
Kelowna, British Columbia, Canada, V1W 4V5
Actively Recruiting
15
Lima's Excellence in Allergy and Dermatology Research (LEADER) Inc.
Hamilton, Ontario, Canada, L8L 3C3
Actively Recruiting
16
Investigational Site Number : 1240009
Toronto, Ontario, Canada, M4E 1R7
Actively Recruiting
17
Investigational Site Number: 1240005
Québec, Quebec, Canada, G1W 4R4
Actively Recruiting
18
Park Dermatology - Site number: 1240007
Sherwood Park, Canada, T8H 0P1
Actively Recruiting
19
Investigational Site Number: 1520003
Santiago, Reg Metropolitana de Santiago, Chile, 7580206
Actively Recruiting
20
Investigational Site Number: 1520002
Santiago, Reg Metropolitana de Santiago, Chile, 7640881
Actively Recruiting
21
Investigational Site Number: 1520001
Santiago, Reg Metropolitana de Santiago, Chile, 8380465
Actively Recruiting
22
Investigational Site Number: 1520005
Santiago, Reg Metropolitana de Santiago, Chile, 8420383
Actively Recruiting
23
Investigational Site Number : 1560002
Chengdu, China, 610041
Actively Recruiting
24
Investigational Site Number : 1560001
Guangzhou, China, 510018
Actively Recruiting
25
Investigational Site Number : 1560005
Ürümqi, China, 830001
Actively Recruiting
26
Investigational Site Number: 2030002
Ostrava, Czechia, 702 00
Actively Recruiting
27
Investigational Site Number: 2030003
Ostrava, Czechia, 708 52
Actively Recruiting
28
Investigational Site Number: 2030001
Prague, Czechia, 110 00
Actively Recruiting
29
Investigational Site Number: 2030004
Prague, Czechia, 150 06
Actively Recruiting
30
Investigational Site Number: 2500001
Antony, France, 92160
Actively Recruiting
31
Investigational Site Number: 2500004
Bezannes, France, 51430
Actively Recruiting
32
Investigational Site Number : 2500003
Bordeaux, France, 33000
Actively Recruiting
33
Investigational Site Number : 2500002
Lyon, France, 69003
Actively Recruiting
34
Investigational Site Number : 2500006
Saint-Priest-en-Jarez, France, 42270
Actively Recruiting
35
Investigational Site Number: 2500007
Toulouse, France, 31059
Actively Recruiting
36
Investigational Site Number : 2760002
Bochum, Germany, 44791
Actively Recruiting
37
Investigational Site Number : 2760008
Bramsche, Germany, 49565
Actively Recruiting
38
Investigational Site Number : 2760003
Frankfurt, Germany, 60590
Actively Recruiting
39
Investigational Site Number : 2760005
Kiel, Germany, 24105
Actively Recruiting
40
Investigational Site Number : 2760004
Mainz, Germany, 55131
Actively Recruiting
41
Investigational Site Number : 2760001
Münster, Germany, 48149
Actively Recruiting
42
Investigational Site Number : 2760006
Würzburg, Germany, 97080
Actively Recruiting
43
Investigational Site Number : 3000001
Athens, Greece, 161 21
Actively Recruiting
44
Investigational Site Number : 3000005
Athens, Greece, 161 21
Actively Recruiting
45
Investigational Site Number : 3000004
Thessaloniki, Greece, 564 29
Actively Recruiting
46
Site Number: 3480001
Debrecen, Gangwon-do, Hungary, 4032
Actively Recruiting
47
Investigational Site Number: 3480003
Pécs, Hungary, 7632
Actively Recruiting
48
Investigational Site Number : 3480004
Székesfehérvár, Hungary, 8000
Actively Recruiting
49
Investigational Site Number: 3760002
Jerusalem, Israel, 9112001
Actively Recruiting
50
Investigational Site Number: 3760001
Tel Aviv, Israel, 6423906
Actively Recruiting
51
Investigational Site Number: 3800002
Milan, Milano, Italy, 20122
Actively Recruiting
52
Istituto Dermatologico San Gallicano, IRCCS - Site Number : 3800004
Roma, Italy, 00144
Actively Recruiting
53
Meiwa Hospital
Nishinomiya, Hyōgo, Japan, 663-8186
Actively Recruiting
54
University of the Ryukyus Hospital - Site Number: 3920002
Nishihara, Okinawa, Japan, 903-0215
Actively Recruiting
55
Nihon University Itabashi Hospital
Tokyo, Japan, 173-8610
Actively Recruiting
56
Investigational Site Number : 5280002
Groningen, Netherlands, 9713 GR
Actively Recruiting
57
Investigational Site Number: 6160001
Wroclaw, Lower Silesian Voivodeship, Poland, 50-566
Actively Recruiting
58
Investigational Site Number: 6160003
Lodz, Lódzkie, Poland, 90-265
Actively Recruiting
59
Investigational Site Number: 6160002
Warsaw, Masovian Voivodeship, Poland, 02-507
Actively Recruiting
60
Grupo Dermatologico de Carolina- Site Number : 8400023
Carolina, Puerto Rico, 00985
Actively Recruiting
61
Investigational Site Number: 7240006
Santiago de Compostela, A Coruña [La Coruña], Spain, 15706
Actively Recruiting
62
Investigational Site Number: 7240003
Las Palmas de Gran Canaria, Las Palmas, Spain, 35010
Actively Recruiting
63
Investigational Site Number: 7240002
Manises, Valencia, Spain, 46940
Actively Recruiting
64
Investigational Site Number: 7240004
Cadiz, Spain, 11009
Actively Recruiting
65
Investigational Site Number : 7240007
Granada, Spain, 18014
Actively Recruiting
66
Investigational Site Number: 7240005
Madrid, Spain, 28007
Actively Recruiting
67
Investigational Site Number: 7240001
Madrid, Spain, 28046
Actively Recruiting
68
Investigational Site Number : 8260008
London, England, United Kingdom, E1 1BB
Actively Recruiting
69
Investigational Site Number : 8260006
Leeds, United Kingdom, LS9 7TF
Actively Recruiting
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here